Search
New Mexico Paid Clinical Trials
A listing of 419 clinical trials in New Mexico actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
397 - 408 of 419
New Mexico is currently home to 419 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Albuquerque, Santa Fe, Las Cruces and Farmington. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Chronic Cough Research Study
Recruiting
Are you tired of living with chronic cough? Our research study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough.
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
Conditions:
Chronic Cough
Refractory or Unexplained Chronic Cough
Cough
Asthma
Sinusitis
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Featured Trial
Stroke Clinical Study
Recruiting
A clinical study for people that suffer with Stroke
Conditions:
Stroke
Featured Trial
Chronic Kidney Disease (CKD) Clinical Study
Recruiting
A clinical study for people that suffer with Chronic Kidney Disease (CKD)
Conditions:
Chronic Kidney Disease (CKD)
REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1
Recruiting
A Phase 2/3 study to investigate the efficacy and safety of luveltamab tazevibulin versus IC chemotherapy in women with ovarian cancer (including fallopian tube or primary peritoneal cancers) expressing FOLR1.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
08/27/2024
Locations: Optimum Clinical Research Group, Albuquerque, New Mexico
Conditions: Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Platinum-resistant Ovarian Cancer
Telehealth-Enabled Versus In-Person Parent-Mediated Behavioral Treatment for Challenging Behaviors in Children With ASD
Recruiting
The purpose of the research is to determine whether parent-mediated behavior therapy for challenging behavior commonly displayed by children with autism spectrum disorder (ASD) can be as effective when delivered via telehealth as when delivered in-person.
Gender:
ALL
Ages:
Between 2 years and 7 years
Trial Updated:
08/23/2024
Locations: Behavior Change Institute, Alamogordo, New Mexico
Conditions: Autism Spectrum Disorder
S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration
Recruiting
Patients are enrolled to screening (Reg Step 1) prior to or after ASCT but prior to Reg Step 2. Patients are followed until they will begin Maintenance and then registered to Reg Step 2 (first randomization). Patients are randomized between Lenalidomide for 2 years and Lenalidomide + Daratumumab/rHuPH20. After 2 years of Maintenance, MRD is assessed to guide further therapy. MRD-positive patients will continue with the assigned treatment. MRD-negative patients will be further randomized (Reg Ste... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
08/21/2024
Locations: University of New Mexico Cancer Center, Albuquerque, New Mexico
Conditions: Multiple Myeloma
Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial
Recruiting
This phase III trial compares the effect of adding surgery to a standard of care immunotherapy-based drug combination versus a standard of care immunotherapy-based drug combination alone in treating patients with kidney cancer that has spread to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as nivolumab, ipilimumab, pembrolizumab, and avelumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow an... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/14/2024
Locations: University of New Mexico Cancer Center, Albuquerque, New Mexico
Conditions: Metastatic Clear Cell Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8
The Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Adult Subjects With Immune Thrombocytopenia (ITP)
Recruiting
This is an open-label, multicenter study to evaluate the safety, tolerability, and efficacy of HMPL-523 in adult subjects with ITP.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/13/2024
Locations: San Juan Oncology Associates, Farmington, New Mexico
Conditions: Immune Thrombocytopenia, Blood Platelet Disorder, Hematologic Diseases, Purpura, Thrombocytopenic, Purpura, Blood Coagulation Disorder, Thrombotic Microangiopathies, Hemorrhagic Disorders, Autoimmune Diseases, Immune System Diseases, Hemorrhage, Pathologic Processes, Skin Manifestations, Thrombocytopenia, Purpura, Thrombocytopenic, Idiopathic, Primary Immune Thrombocytopenia, ITP - Immune Thrombocytopenia
Treatment of Brain AVMs (TOBAS) Study
Recruiting
The objectives of this study and registry are to offer the best management possible for patients with brain arteriovenous malformations (AVMs) (ruptured or unruptured) in terms of long-term outcomes, despite the presence of uncertainty. Management may include interventional therapy (with endovascular procedures, neurosurgery, or radiotherapy, alone or in combination) or conservative management.
The trial has been designed to test a) whether medical management or interventional therapy will redu... Read More
Gender:
ALL
Ages:
5 years and above
Trial Updated:
08/13/2024
Locations: University of New Mexico Health Sciences Center, Albuquerque, New Mexico
Conditions: Unruptured Brain Arteriovenous Malformation, Ruptured Brain Arteriovenous Malformation, Arteriovenous Malformations, AVM, BAVM
The Healthy Kids+ Initiative: Promoting Active Living Through Healthy Choices
Recruiting
The study will test the effectiveness and examine the sustained effects of weekly programming on enhancing (1) lifestyle behaviors (physical activity, dietary intake, use of technology, amount of sleep), (2) self-efficacy, (3) self-esteem, and (4) readiness to change among children ages 8-11 years.
Gender:
ALL
Ages:
Between 8 years and 11 years
Trial Updated:
07/18/2024
Locations: Loma Heights Elementary School, Las Cruces, New Mexico
Conditions: Health Behavior
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
Recruiting
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-sma... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/29/2024
Locations: Lovelace Medical Center-Downtown, Albuquerque, New Mexico
Conditions: ALK Gene Rearrangement, ALK Gene Translocation, ALK Positive, Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7
Suicide in Urban Natives: Detection and Networks to Combat Events
Recruiting
This study compares the effectiveness of a program to detect and manage suicide risk among American-Indian and Alaska Native (AI/AN) youth. Half of the participants will receive caring text messages to reduce suicidal thoughts, attempts, and hospitalizations and to increase engagement, social connectedness, and resilience in at-risk youth. The other half will receive usual care that does not include the caring text messages.
Gender:
ALL
Ages:
Between 18 years and 34 years
Trial Updated:
06/26/2024
Locations: First Nations Community HealthSource, Albuquerque, New Mexico
Conditions: Suicide Prevention
Post Approval Study2: Hintermann Series H3 Total Ankle Replacement System
Recruiting
The H3 TAR Prosthesis was approved by FDA (P160036) on June 4, 2019. Continued approval of the premarket approval application (PMA) is contingent upon the submission of periodic reports (Annual Report), required under 21 CFR 814.84. In order to provide continued reasonable assurance of the safety and effectiveness of the PMA device, data from this post-approval study must be submitted to FDA in a PMA Post-Approval Study Report per the requirements set forth in the approval.
Gender:
ALL
Ages:
21 years and above
Trial Updated:
06/24/2024
Locations: New Mexico Bone and Joint Institute, Alamogordo, New Mexico
Conditions: Osteoarthritis Ankle, Post-Traumatic Osteoarthritis of Ankle, Osteoarthritis of Ankle Secondary to Inflammatory Arthritis (Disorder)
PROMISE III: Percutaneous Deep Vein Arterialization for the Treatment of Late-Stage Chronic Limb-Threatening Ischemia
Recruiting
A prospective, single-arm, multi-center study designed to gather additional information on the LimFlow System.
Gender:
ALL
Ages:
Between 18 years and 95 years
Trial Updated:
05/31/2024
Locations: Presbyterian Healthcare, Albuquerque, New Mexico
Conditions: Critical Limb Ischemia, Peripheral Arterial Disease, Chronic Limb-Threatening Ischemia
Surveillance and Treatment to Prevent Fetal Atrioventricular Block Likely to Occur Quickly (STOP BLOQ)
Recruiting
Fetal complete (i.e., third degree, 3°) atrioventricular block (AVB), identified in the 2nd trimester of pregnancy in an otherwise normally developing heart, is almost universally associated with maternal anti-Ro autoantibodies and results in death in a fifth of cases. To date treatment of 3° AVB has been ineffective in restoring normal rhythm (NR) which may be because current surveillance is limited to once- weekly fetal echocardiograms. It is hypothesized that there may be a vital transition p... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/17/2024
Locations: Perinatal Associates of New Mexico, Rio Rancho, New Mexico
Conditions: AVB - Atrioventricular Block, Fetal AVB